Study: NCT01823835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810
Description: GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).